Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.The company offers treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 10, 2018 | Series A | $54M | 1 | Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | Yes | Series A |